CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Revenue:
Revenue	$ 670,534		$ 366,260		$ 270,245
Costs and operating expenses:
Cost of product revenue	279,280		156,634		119,099
Research and development	34,274		20,182		19,450
Selling, general and administrative	183,866		119,621		95,613
Contingent consideration expense	5,865
Total costs and operating expenses	503,285		296,437		234,162
Income from operations	167,249		69,823		36,083
Other (expenses) income:
Investment income	176		1,741		5,324
Loss on conversion of debt	(13)				(5,650)
Interest expense	(12,714)		(12,133)		(9,292)
Other expenses	(1,155)		(214)		(314)
Other expenses, net	(13,706)		(10,606)		(9,932)
Income before income taxes	153,543		59,217		26,151
Income tax provision (benefit)	25,252		(709)		4,740
Net income	$ 128,291		$ 59,926		$ 21,411
Earnings per share:
Basic	$ 2.33		$ 1.14		$ 0.44
Diluted	$ 2.24		$ 1.11		$ 0.44
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic	55,015		52,554		48,343
Diluted	57,264		53,892		49,206
Net income	$ 128,291		$ 59,926		$ 21,411
Other comprehensive income (loss):
Foreign currency translation adjustment	(18,971)		17,112		(3,134)
Comprehensive income	109,320		77,038		18,277
Products
Revenue:
Revenue	670,319	[1]	366,136	[2]	270,097	[3]
Royalty and Other Revenue
Revenue:
Revenue	$ 215		$ 124		$ 148

[1] 2021 revenue for filtration products includes revenue related to Polymem from July 1, 2021 as well as BioFlex and NTM from December 16, 2021 through December 31, 2021. 2021 revenue for proteins products includes revenue related to Avitide from September 20, 2021 through December 31, 2021.

[2] 2020 revenue for filtration products includes revenue related to EMT from July 13, 2020, NMS from October 20, 2020 and ARTeSYN from December 3, 2020 through December 31, 2020.

[3] 2019 revenue includes process analytics revenue related to C Technologies from June 1, 2019 through December 31, 2019.